Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Cancer Institute (NCI)

National Institute on Drug Abuse (NIDA)

Funding Opportunity Title
Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
Activity Code

U24 Resource-Related Research Projects – Cooperative Agreements

Announcement Type
New
Related Notices

NOT-OD-23-012 Reminder: FORMS-H Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available

NOT-CA-23-006 - Notice of Pre-Application Webinar for RFA-CA-22-052 and RFA-CA-22-053

NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022

Funding Opportunity Announcement (FOA) Number
RFA-CA-22-053
Companion Funding Opportunity
RFA-CA-22-052 , U01 Research Project (Cooperative Agreements)
Assistance Listing Number(s)
93.393, 93.279
Funding Opportunity Purpose

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute on Drug Abuse (NIDA) will support a coordinating center to facilitate coordination of research activities between the new Cooperative Agreements U01 awards supported under the companion RFA-CA-22-052.

The coordinating center will have several responsibilities, including, but not limited to provide logistical and administrative support to the U01 awards supported under the companion RFA-CA-22-052. Their responsibilities will involve working with the U01 awardees to facilitate sharing of data collection instruments, measures and resources, and identify a core set of questions to be included in data collection across the funded studies. They will also create standard operating procedures and ensure best practices are followed for data and biospecimen collection and analytical assays. In addition, they will facilitate communication across cohorts, coordinate topical working groups around key scientific issues that cut across individual U01 projects, provide meeting support, create and maintain a project website, and facilitate deposition of data to NIH repositories.

Key Dates

Posted Date
October 03, 2022
Open Date (Earliest Submission Date)
January 17, 2023
Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
February 17, 2023 Not Applicable Not Applicable June 2023 August 2023 September 2023

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

No late applications will be accepted for this Funding Opportunity Announcement.

Expiration Date
February 18, 2023
Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.


  4. Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Purpose

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute on Drug Abuse (NIDA) solicit applications for a Coordinating Center, which will facilitate coordination of research activities across new U01 awards supported under companion RFA-CA-22-052. The goal of the Benefits and Harms of Cannabis Use in Cancer Patients Observational Research Studies is to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment.

Applicants responding to the coordinating center FOA are expected to familiarize themselves with the companion FOA (RFA-CA-22-052) and the requirements for the U01 projects related to the activities and responsibilities required for the Coordinating Center.

The main role of the coordinating center will be to facilitate and coordinate the research activities of the U01 prospective cohort studies. The coordinating center will be expected to do this by communication, coordination, and collaboration across the U01 awarded studies and in coordination with NIH program staff.

Key Terms for This FOA

Cannabis and Cannabinoids: In this FOA, the terms “cannabis and cannabinoids” refer to any cannabis plant (e.g., marijuana), cannabis-derived products/cannabinoids, tetrahydrocannabinol (THC), cannabidiol (CBD) -only products, prescription cannabinoids such as Dronabinol and Nabilone, commercially available as Marinol (dronabinol capsules), Syndros (dronabinol oral solution), and Cesamet (nabilone), or any other products made with or derived from cannabis.

Prospective Cohort Study: A longitudinal study that compares and follows a group of people who are exposed and unexposed to a factor of interest, in this case comparing cancer patients using cannabis and cannabinoid products to those not using these products and assessing health outcomes.

Cancer Patients in Active Treatment: Cancer patients enrolled during active treatment include those undergoing surgery and/or radiation and/or other systemic therapy including those with recurrent disease.

U01 prospective cohort studies: Includes four awards funded through the companion RFA-CA-22-052.

Background

The U.S. legal landscape of medical and nonmedical cannabis and cannabinoid (cannabis-derived products) use has changed dramatically over the past decade with wide variation in state policies. Concurrently, the available delivery methods of these products have also undergone substantial changes and include edibles, oils, tinctures, topicals, and inhaled forms. These changes in legalization and types of cannabis and cannabinoid products have increased access and use among the general US population. Despite this increase in cannabis and cannabinoid use, research on its health effects, including both the potential benefits and harms, remains limited.

While most US medical oncologists regularly engage in discussions about cannabis and cannabinoid use with patients, few oncologists feel sufficiently informed to make recommendations. Nonetheless, recent surveys consistently demonstrate that at least a quarter of cancer patients use cannabis and cannabinoids for symptom management during their treatment. Cancer patients use cannabis and cannabinoids during treatment to manage common symptoms such as anxiety, loss of appetite, nausea, pain, and sleep disturbance. While many patients report beneficial effects, there is also potential for harms such as cardiac issues and cognitive impairment. In addition, three recent observational studies demonstrate that cancer patients using cannabis during immunotherapy were significantly more likely than those not reporting cannabis use to show a shorter time to tumor progression.

The rapidly increasing availability of cannabis and cannabinoid products, their delivery methods, and the dearth of information available on their harms and benefits during treatment, call for a rapid infusion of multiple studies addressing cannabis and cannabinoid use among cancer patients.

Research Objectives and Requirements

The U24 coordinating center will assist and support the prospective cohort studies funded under RFA-CA-22-052. Applicants responding to this coordinating center FOA are expected to familiarize themselves with the companion FOA (RFA-CA-22-052) and the requirements for the U01 projects related to the activities and responsibilities required of the coordinating center. The coordinating center will be responsible for providing coordinated support to the research studies as outlined below.

Main Scientific Responsibilities of the Coordinating Center

In consultation with the U01 awardees and NIH program staff, the coordinating center will be responsible for several tasks including the following:

  • Provide logistical and administrative support for the U01 awarded cohort studies by providing state-of-the-art cross-study communication, a project website, a Principal Investigators (PIs) team discussion space, and working with NIH program staff and PIs to organize annual and interim meetings as needed.
  • Work with the U01 awardees to identify, assist, and develop a core set of questions (such as cannabis and cannabinoid consumption), as appropriate given the study population, to be included in data collection across the cohort studies.
  • Facilitate sharing of data collection instruments, measures, and resources and assist with coding efforts across the U01 awarded projects.
  • Create standard operating procedures (SOPs) and facilitate best practices across studies for data collection and as well as if biospecimen collection and analytical assays are proposed.
  • Using the NCI Best Practice guidelines as a reference (https://biospecimens.cancer.gov/bestpractices/), review protocols and quality control metrics regarding collection, processing, storage, and retrieval of samples according to SOPs. This is not a central biospecimen repository and the coordinating center will not be storing samples and not managing the distribution of sample requests.
  • Coordinate topical working groups around key scientific issues and emerging scientific topics that cut across individual projects.
  • Work with the U01 awardees to ensure that the data are findable, accessible, interoperable, and reusable (FAIR) to make the data and results maximally useful to the public; see https://www.go-fair.org/fair-principles/). See instructions for Resource Sharing Plans as provided in SF424 Application Guide.
  • Work with the U01 awardees to facilitate data sharing and the timeline for sharing, deposition of data to NIH designated repositories such as dbGaP, process for accessing data, any limitations, etc. It is expected that there will be broad access to the data through controlled-access data repositories. U24 awardees will be expected to be familiar with data submission to the NIH designated repositories.

Coordinating Center Research Team Expertise and Composition

To fulfill the main responsibilities stated above, the coordinating center team will be expected to have appropriate expertise and experience in such areas as:

  • Data management using applicable tools;
  • Successful partnerships with multiple study teams across diverse settings and regions in the design, implementation, and completion of research cohort studies;
  • Effective communications across scientific teams, research participants, and NIH program staff;
  • Website development, file management, organization, and maintenance;
  • Team discussion space development, file management, organization, and maintenance for the Principal Investigators (PIs) of the U01s funded under the companion RFA-CA-22-052;
  • Organization of virtual and in-person grantee and scientific meetings;
  • Knowledge of NIH data sharing policies (https://sharing.nih.gov/data-management-and-sharing-policy/about-data-management-and-sharing-policy/data-management-and-sharing-policy-overview), FAIR principles (Findable, Accessible, Interoperable, Reusable; https://www.go-fair.org/fair-principles/) and experience with deposition of data to NIH designated repositories such as dbGaP.

The composition of the research team for the proposed coordinating center must ensure the requisite expertise identified above. In addition, the team should be capable of effective communications and productive collaborations with various stakeholder groups.

Logistical and Administrative Responsibilities of Coordinating Center

In addition to scientific support of the U01 awarded projects, the coordinating center must be able to provide logistical and administrative support to each research project funded under companion RFA-CA-22-052, and other activities, including but not limited to the following:

  • Provision of a public website for communication and sharing of activities, events, and resources of the awarded studies;
  • Develop and support a team discussion space to facilitate sharing of activities, events, and resources of the awarded studies for the Principal Investigators (PIs) of the U01s funded under the companion RFA-CA-22-052;
  • Organizational and logistical support for establishing and coordinating topical working groups around key scientific issues that cut across individual projects;
  • Supporting standards and mechanisms for publicly sharing data, resources, and common measures developed and utilized across the individual projects, including by the coordinating center;
  • Organizing and supporting the logistics of the in-person annual investigators meetings at a location identified by NIH program staff in years 1, 3, and 5;
  • Organizing and supporting the logistics of the virtual annual investigators meetings in years 2 and 4; and,
  • Organizing and supporting the logistics of interim virtual meetings (e.g., monthly meetings) as appropriate and determined by NIH program staff and steering committee.

Program Structure

The program will include four new cohorts (RFA-CA-22-052) and a coordinating center (this FOA) to integrate efforts across the individual cohorts. Awardees will also identify shared resources that can support needs across the cohorts and maximize the collaborative nature and impact of the program. Members will be required to participate in yearly meetings (in-person year 1,3, and 5 of award period) and virtual (year 2 and 4 of award period) as well as interim virtual meetings as needed for the exchange of scientific information across the cohorts. The coordinating center, in conjunction with NIH program staff, will facilitate collaborations among the cohorts. The program will be governed by a steering committee comprised of representatives from the funded cohorts, the coordinating center, and NIH program staff.

The U24 awardee will be required to interact closely with the new U01 cohort studies (RFA-CA-22-052), and NIH program staff to advance scientific research related to understanding the benefits and harms of cannabis and cannabinoids among cancer patients in active treatment, as outlined below.

  • Scientific Interactions with U01 awardees: Each cohort will collaborate with the coordinating center as required to share data collection instruments, measures and resources, identify and develop a core set of questions, discuss shared challenges and, as appropriate, share protocols for the collection of biological specimens.
  • Scientific Interactions with Steering Committee: The steering committee may establish work groups as needed for specific topics and / or emerging scientific opportunities that are shared across some of all the research of the cohorts. Members of work groups will include investigators from each cohort, coordinating center, and NIH program staff.

Program Governance

The steering committee will be comprised of the PI of each cohort and the coordinating center, and NIH program staff. Though the steering committee will make recommendations, NIH program staff will have final authority to approve any proposed recommendations, and activities must comply with NIH, DHHS, and Federal Guidelines.

Additional details on the composition and functions of the steering committee are provided in Section VI.2, Cooperative Agreement Terms, and Conditions of Award.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed
New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Not Allowed: Only accepting applications that do not propose clinical trials.

Funds Available and Anticipated Number of Awards

NCI intends to commit $800,000 in FY 2023 to fund one award. Future year amounts are anticipated to be at the same levels but will ultimately depend on annual appropriations.

Award Budget

Application budgets are limited $500,000 direct costs per year.

Award Project Period

The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. 

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • System for Award Management (SAM)– Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
    • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
    • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
  • eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to

Kelly K Filipski, PhD, MPH
National Cancer Institute (NCI)
Telephone: 240-276-6841
Email: Kelly.Filipski@nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed.

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

Travel Budget: Applicants are required to budget funds for PD/PI(s) for travel to attend an annual grantee meeting at a location determined by NIH program staff in years 1, 3, and 5 of the grant period. In years 2 and 4 of the grant period, annual grantee meetings will be held virtually. The purpose of these meetings will be to bring together investigators to share common research areas and topics across studies and share knowledge, progress, and findings, and allow for rapid translation of results. The budget of the U24 is limited to $500,000 in direct costs per year.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Specific Aims: Outline the general objectives of the proposed coordinating center, the overall approach for achieving these goals, and how the approach will support Research Projects.

Research Strategy: Applicants must organize the Research Strategy into the subsections identified below. Applicants may include other sections as needed but must include the information requested below.

Subsection A: Administrative Processes

  • Explain the capabilities in coordinating prospective cohort studies and facilitating the development of a set of core questions using survey tools that can be applicable to cannabis and cannabinoid use in cancer patients in active treatment.
  • Emphasize how the combined, interdisciplinary expertise of the team will meet the needs of the Coordination Center activities including experience with supporting prospective research studies.  Do not repeat information provided in biosketches.
  • Describe the organizational and governing structure for the Coordinating Center, lines of authority, and decision-making processes.
  • A proposed timeline of planned activities.
  • Processes for facilitating meetings (e.g., annual grantee meeting, interim meetings).

Subsection B: Core Set of Questions

  • Propose a process including a timeline for interacting with the individual awarded studies, the steering committee and the NIH program staff to identify, assist, and develop a core set of questions relevant to cannabis and cannabinoid use assessment and patient reported outcome measures from traditional questionnaires and innovative technologies, and biological samples.

Subsection C: Supporting Research

  • Propose a process for supporting the coordination of activities across the awarded studies funded under the companion RFA-CA-22-052 that involve assessing the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment.
  • Propose a plan to facilitate sharing data collection instruments, measures and resources across the cohort studies.

Subsection D: Facilitating Data Sharing and Dissemination

Applicants must provide a detailed plan for the facilitation of data, survey instruments, and resource sharing from across the cohorts. The data/resource sharing plans must be consistent with NIH data sharing policies and follow Findable, Accessible, Interoperable, Reusable (FAIR) principles (see https://www.go-fair.org/fair-principles/). Instructions for Resource Sharing Plans is provided in SF424 Application Guide. Support the U01 awarded cohorts in the management and decision-making process that promote data sharing, data deposition to NIH designated data repositories, process for accessing data, any limitations, etc. The plan should include steps for creating standard operating procedures, accessibility requirements, and review process for granting access to the research community, and dissemination of that information.

Letters of Support: Include letters of support from participating institutions and organizations who must agree to ensure that data from the cohorts is shared.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

  • All applications, regardless of the amount of direct costs requested for any one year, must include a Data Sharing Plan.
  • The coordinating center will ensure that data from the U01 cohorts are shared in accordance with the required data-sharing plans. Support the U01 awarded cohorts in the management and address decision-making process that promote data sharing, timeline for sharing, data deposition to NIH designated data repositories, process for accessing data, any limitations, etc. The plan should also include steps for creating standard operating procedures, accessibility requirements, and review process for granting access to the research community, and dissemination of that information. The data sharing plan will become a term and condition of award.
  • The coordinating center should be able to facilitate the transfer of data to an existing NIH data repository (e.g., dbGaP) while supporting and facilitating best practices for the collection of common measures/assessments across studies.
  • The following may also apply:
    • Data sharing must be compliant with NIH data sharing policies, including the NIH Genomic Data Sharing Policy (https://datascience.cancer.gov/data-sharing/genomic-data-sharing) with the extent and type of data that will be shared, the data repository to which the data will be submitted (repository must be publicly accessible or controlled access, but is not limited to NIH repositories, see www.nlm.nih.gov/NIHbmic/nih_data_sharing_repositories.html for a full listing of NIH repositories), and the timeline for the data to be shared after each round of data acquisition.
    • Sharing of resources with broad availability of policies, practices, materials, and tools to facilitate collaboration, transparency, and reproducibility is encouraged.
    • Sharing of study data in a timely manner with appropriate privacy and confidentiality protections to facilitate further research, reuse of data, and replication is encouraged.

Appendix:

Only limited Appendix materials are allowed.

Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by NCI, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the proposed Center address the needs of the research projects that it will coordinate? Is the scope of activities proposed for the Center appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the research projects?

Specific to this FOA:

How well does the coordinating center demonstrate its ability to serve the goals of the group of prospective cohort studies (U01s) related to understanding the benefits and harms of cannabis and cannabinoid use in cancer patients in active treatment?

 

Are the PD(s)/PI(s) and other personnel well suited to their roles in the Center? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing adjective research? Do the investigators demonstrate significant experience with coordinating collaborative clinical research? If the Center is multi-PD/PI, do the investigators have complementary and integrated expertise and skills; are their leadership approach, governance, plans for conflict resolution, and organizational structure appropriate for the Center? Does the applicant have experience overseeing selection and management of subawards, if needed?

 

Does the application propose novel organizational concepts or management strategies in coordinating the research projects the Center will serve? Are the concepts, strategies, or instrumentation novel to one type of research program or applicable in a broad sense? Is a refinement, improvement, or new application of organizational concepts or management strategies proposed?

 

Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the research projects the Center will serve? Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the projects as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the projects is in the early stages of operation, does the proposed strategy adequately establish feasibility and manage the risks associated with the activities of the projects? Are an appropriate plan for work-flow and a well-established timeline proposed? Have the investigators presented adequate plans to ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects?o ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects?

Specific to this FOA: 

How well does the application contain acceptable plans for facilitating data sharing and publicly accessible or controlled access, and resources? How well does the proposed approach allow efficient management upkeep of a public website and Principal Investigator specific collaborative website? How well does the proposed approach allow for the coordinating center personnel and collaborative tools to enable speedy research planning and implementation? How appropriate are the plans for administrative and logistical support of the U01 awards? How well aligned is the scientific support for the U01 research projects?

How adequate is the proposed strategy to establish feasibility and manage the risks associated with the activities of the projects? To what extent is there an appropriate plan for workflow with a well-established timeline proposed?

 

Will the institutional environment in which the Center will operate contribute to the probability of success in facilitating the research projects it serves? Are the institutional support, equipment and other physical resources available to the investigators adequate for the Center proposed? Will the Center benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

 

Is the study timeline described in detail, taking into account start-up activities? Is the projected timeline feasible and well justified?

 

For research that involves human subjects but does not involve one of the  categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the  categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

 

Not applicable

 

Not applicable

 

Not applicable

 

Have the investigators stated their abilities to collaborate NIH program staff and the U01 awardees to identify, assist and develop a core set of questions such as measurement of cannabis and cannabinoid use, social determinants of health, health outcomes and patient reported outcomes?

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

 

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

 

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

 

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate scientific review group(s) convened by the NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a scientific review group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: Generaland Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:

If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identify, sexual orientation, and pregnancy). This includes ensuring programs are accessible to persons with limited English proficiency and persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of the award are in addition to, and not in lieu of, otherwise applicable US Office of Management and Budget (OMB) 2 CFR Part 200 Administrative Regulations, US Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75 and 2 CFR 200, NIH Grants Policy Statement (which implements the aforementioned HHS Regulations (45 CFR Part 75), and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipents for the project as a whole, although specific tasks and activities may be shared among the recipients and NIH as defined below.

The U24 PD(s)/PI(s) will have the primary responsibility for the following:

  • Defining the overall research objectives;
  • Determining approaches, designing protocols, setting project aims, and overseeing the conduct of the research;
  • Overseeing the conduct of the research and ensuring its scientific rigor;
  • Ensuring compliance with the applicable mandatory regulations (including protection of human subjects) as required by specific research activities;
  • Adhering to the NIH policies regarding intellectual property, data release, and other policies that might be established during the program;
  • Coordinating the submittion of updates from the U01 cohorts to the NIH on progress and problems;
  • Implementing guidelines and procedures developed by the steering committee;
  • Participating in teleconferences with NIH program staff, as needed;
  • Attending in person and virtual annual meetings to be held in location selected by NIH program staff as well as virtual interim meetings as needed;
  • Retaining custody of and having primary rights to the data, technologies, and software developed under these awards, subject to government rights of access consistent with current HHS, PHS, and NIH policies;
  • The PD(s)/PI(s) assume(s) responsibility and accountability to the applicant organization officials and to the NIH program staff for the performance and proper conduct of the research supported by the award in accordance with the terms of the award.

NIH program staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards as described below:

One or more designated NIH program staff members will have substantial involvement as project scientist(s).

Additionally, an NIH program director acting as program official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.

The responsibilities of substantially involved NIH program staff members will include the following activities:

  • Participating as voting members in the steering committee;
  • Advising on innovative approaches for sharing results from the U01 to key stakeholder organizations (e.g., professional societies, community engagement groups) in user-friendly formats (e.g., briefs, summaries) that extend beyond the traditional peer-reviewed publications or scientific conference presentations;
  • Participating in teleconferences with the Principal Investigators (PIs) and key personnel of the U01s to monitor progress;
  • Providing scientific input on the U01, including a core set of questions, biological samples collections, and methodological and statistical considerations; participant recruitment, enrollment, and retention; and data analysis and interpretation of study findings;
  • Along with coordinating center, participate in organizing and coordinating recipient meetings (in-person and virtual meetings);
  • Participating in work groups;
  • Contributing, as appropriate, to scientific manuscripts and other scientific and scholarly activities (e.g., oral presentations, poster presentations) resulting from the U01 grant;
  • Facilitate collaborations between the recipients and other NIH-sponsored programs investigators, or organizations;
  • Assisting with the coordination of efforts that may contribute to the projects’ goals;
  • Organizing and participating in webinars with PIs of the U01 cohorts to monitor progress and facilitate cooperation;
  • Monitoring progress of the projects towards meeting goals of the U01 grant; and
  • Stimulating interactions among recipients.

Areas of joint responsibility include the following:

The steering committee will serve as the governing body for formed by the U01 recipients funded under RFA-CA-22-052 and U24 recipient funded under RFA-CA-22-053 will form together with the NIH.

The steering committee will consist of the following voting members:

  • The Principal Investigators (PIs) from each cohort U01 award (one vote per cohort);
  • The PIs from the coordinating center (one vote for the coordinating center);
  • The NIH-assigned project scientist(s) who collectively will have one vote; and
  • A chair of the steering committee will be selected at the first meeting. The chair will serve a term of 12-months.

The steering committee, U01 recipients, the U24 coordinating center, and the NIH program staff will meet as needed virtually throughout the award period. Formal annual meetings will take place, with in person meeting held in years 1,3, and 5 at locations selected by the NIH program staff and virtual meetings in years 2 and 4.

The steering committee may decide to establish work groups for specific purposes. The NIH Project Scientists will serve on such sub-committees, as they deem appropriate.

The main responsibilities of the steering committee will include the following elements:

  • Addressing and coordinating aspects relevant to research and the coordinating center;
  • Developing, as needed, overall policies and processes applicable to all recipients;
  • Set agendas for what policies and procedures should be developed that enable the evaluation of cannabis and cannabinoid use in cancer patients in active treatment research program;
  • Attending meetings to review progress across the U01 awarded projects;
  • Identifying scientific writing groups for manuscripts and oral and poster presentations at professional societies and scholarly meetings;
  • Establishing work groups as needed; and
  • Facilitating communications among recipients, e.g., to share ideas, discuss solutions to technical issues, resolve logistical problems, shared common challenges, etc.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A three-member dispute resolution panel will be convened, consisting of one NIH designee and two designees with expertise in the relevant area, chosen by the other two. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part.

3. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over the threshold.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 – Award Term and Condition for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Scientific/Research Contact(s)

Kelly K Filipski, PhD, MPH
National Cancer Institute (NCI)
Telephone: 240-276-6841
Email: Kelly.Filipski@nih.gov

Evan Sullivan Herrmann
National Institute on Drug Abuse (NIDA)
Phone: 301-443-1428
E-mail: evan.herrmann@nih.gov

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov

Financial/Grants Management Contact(s)

Dawn M. Mitchum
National Cancer Institute (NCI)
Telephone: 240-276-6291
E-mail: dm437a@nih.gov

Pamela G Fleming
National Institute on Drug Abuse (NIDA)
Phone: 301-480-1159
E-mail: pfleming@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.